55694-81-0

Usage

Uses

Used in Pharmaceutical Industry:
1-Methyl-1H-imidazole-2-sulfonyl chloride is utilized as a reagent for the synthesis of various pharmaceutical compounds, contributing to the development of new drugs and therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical sector, 1-Methyl-1H-imidazole-2-sulfonyl chloride is employed as a key component in the synthesis of sulfonylurea herbicides, which are widely used for effective weed control in agricultural settings.
Used in Organic Synthesis:
1-Methyl-1H-iMidazole-2-sulfonyl chloride serves as a building block in the synthesis of various heterocyclic compounds, which are essential in the creation of complex organic molecules with diverse applications in different industries, including pharmaceuticals, materials science, and more.

Upstream product

• 60-56-0 2-Mercapto-1-methylimidazole 

Downstream Products

• 1621914-65-5 1-(4-{[(2S,4R)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-4-(1-methylimidazol-2-ylsulfonyl)piperazine 
• 1359937-95-3 ethyl 1-benzyl-6-(2-(1-methyl-1H-imidazole-2-sulfonamido)ethoxy)-2,3-dihydro-1H-inden-2-ylcarbamate 

Relevant academic research and scientific papers

NaClO2-mediated preparation of pyridine-2-sulfonyl chlorides and synthesis of chiral sulfonamides

A simple method to prepare azaarenesulfonyl chlorides by NaClO2-mediated oxidative chlorination of azaarenethiols have been developed, with water as the solvent. Easy purification by simple extraction and concentration gives the products in good yields. The azaarenesulfonyl chlorides readily undergo condensation with chiral amines to afford chiral sulfonamides.

Design and in vitro activities of N -alkyl- N -[(8- R -2,2-dimethyl-2 H -chromen-6-yl)methyl]heteroarylsulfonamides, novel, small-molecule hypoxia inducible factor-1 pathway inhibitors and anticancer agents

The hypoxia inducible factor (HIF) pathway is an attractive target for cancer, as it controls tumor adaptation to growth under hypoxia and mediates chemotherapy and radiation resistance. We previously discovered 3,4-dimethoxy-N-[(2,2-dimethyl-2H-chromen-6-yl)methyl]-N- phenylbenzenesulfonamide as a novel, small-molecule HIF-1 pathway inhibitor in a high-throughput cell-based assay, but its in vivo delivery is hampered by poor aqueous solubility (0.009 μM in water; log P7.4 = 3.7). Here we describe the synthesis of 12 N-alkyl-N-[(8-R-2,2-dimethyl-2H-chromen-6-yl) methyl]heteroarylsulfonamides, which were designed to possess optimal lipophilicities and aqueous solubilities by in silico calculations. Experimental log P7.4 values of 8 of the 12 new analogs ranged from 1.2-3.1. Aqueous solubilities of three analogs were measured, among which the most soluble N-[(8-methoxy-2,2-dimethyl-2H-chromen-6-yl)methyl]-N-(propan-2-yl) pyridine-2-sulfonamide had an aqueous solubility of 80 μM, e.g., a solubility improvement of ～9000-fold. The pharmacological optimization had limited impact on drug efficacy as the compounds retained IC50 values at or below 5 μM in our HIF-dependent reporter assay.

Sulphonamido-Substituted Cyclohexyl Sulphones for Treatment of Cancer

Compounds of formula (I) are disclosed for treatment of cancer.

CYCLOHEXYL SULPHONES AS GAMMA-SECRETASE INHIBITORS

Compounds of formula (I) inhibit the processing of APP by gamma-secretase, and hence are useful in treating or preventing Alzheimer's disease.

Synthesis of chiral heteroaromatic tetradentate sulfonamide based ligands

We report a facile two step synthesis of chiral tetradentate ligands for late metal complexes. The ligands are easily prepared from trans-1,2- diaminocyclohexane or chiral 1,2-diphenylethylenediamine and a heteroaromatic sulfonyl chloride in the presence of base (K2CO3 or Et3N). These compounds represent a new class of chiral tetradentate N2S2 and N4 based ligands.

Imidazole compounds, processes for their preparation, pharmaceuticals based on these compounds and some intermediates

Imidazole compounds of the formula I STR1 in which R1 =alkyl, R2 and R3 =H, halogen or alkyl, X=OH or an amide radical having certain substituents, processes for their preparation and pharmaceuticals based on these compounds, in particular for the prophylaxis and treatment of circulatory disturbances, especially of disturbances of the microcirculation and of the disorders resulting therefrom, and some novel intermediates for the preparation of the compounds of the formula I, which are 1-methyl-, 1,2-dimethyl- and 1-ethyl-4-imidazolesulfonyl chloride.

1-Heteroarylsulphonyl-2-imino-imidazolidines

Compounds of the class of 1-heteroarylsulphonyl-2-imino-imidazolidines which are substituted in the 3-position by an aliphatic or cycloaliphatic hydrocarbon radical, especially a cycloalkyl radical, and their pharmaceutically acceptable acid addition salts have valuable pharmacological properties. In particular, they possess hypoglycaemic activity and can be used for the treatment of hyperglycaemia in mammals. A specific embodiment is 1-[5-(2-butyramido-ethyl)-2-thienylsulphonyl]-2-imino-5-cyclohexyl-imidazolidine.